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Abstract
Introduction: Fine-grained influenza surveillance data are lacking in the US, hampering our ability to monitor disease spread
at a local scale. Here we evaluate the performances of high-volume electronic medical claims data to assess local and
regional influenza activity.
Material and Methods: We used electronic medical claims data compiled by IMS Health in 480 US locations to create weekly
regional influenza-like-illness (ILI) time series during 2003–2010. IMS Health captured 62% of US outpatient visits in 2009. We
studied the performances of IMS-ILI indicators against reference influenza surveillance datasets, including CDC-ILI
outpatient and laboratory-confirmed influenza data. We estimated correlation in weekly incidences, peak timing and
seasonal intensity across datasets, stratified by 10 regions and four age groups (,5, 5–29, 30–59, and 60+ years). To test
IMS-Health performances at the city level, we compared IMS-ILI indicators to syndromic surveillance data for New York City.
We also used control data on laboratory-confirmed Respiratory Syncytial Virus (RSV) activity to test the specificity of IMS-ILI
for influenza surveillance.
Results: Regional IMS-ILI indicators were highly synchronous with CDC’s reference influenza surveillance data (Pearson
correlation coefficients rho$0.89; range across regions, 0.80–0.97, P,0.001). Seasonal intensity estimates were weakly
correlated across datasets in all age data (rho#0.52), moderately correlated among adults (rho$0.64) and uncorrelated
among school-age children. IMS-ILI indicators were more correlated with reference influenza data than control RSV
indicators (rho = 0.93 with influenza v. rho = 0.33 with RSV, P,0.05). City-level IMS-ILI indicators were highly consistent with
reference syndromic data (rho$0.86).
Conclusion: Medical claims-based ILI indicators accurately capture weekly fluctuations in influenza activity in all US regions
during inter-pandemic and pandemic seasons, and can be broken down by age groups and fine geographical areas. Medical
claims data provide more reliable and fine-grained indicators of influenza activity than other high-volume electronic
algorithms and should be used to augment existing influenza surveillance systems.
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The last decade has seen dramatic developments in influenza
surveillance systems at the regional and national scales. In the US
however, despite intensified surveillance for influenza-like-illness
(ILI) and laboratory-confirmed virus activity [1], the volume of
information remains too sparse for detailed analyses at the state
and city levels [2]. Novel electronic surveillance data streams such
as Twitter and Google Flu Trends provide much higher volume
information; however these algorithms do not always accurately
capture local or national influenza patterns, especially during
pandemics or unusual epidemics [3,4]. Indicators based on
emergency department visits provide solid localized information
on a variety of influenza-related syndromes in near real-time,
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however, these data are not available throughout the US. In
contrast to influenza, relatively little attention has been focused on
respiratory syncytial virus (RSV), although the burden of this
pathogen is increasingly recognized, particularly among pediatric
age groups [5,6,7,8]. In the absence of an RSV vaccine, it is
important to optimize the timing of RSV prophylaxis in high-risk
infants according to the local RSV season, requiring the need for
improved RSV surveillance locally [9,10].
Electronic medical claims data provide a unique source of
information on diagnoses made by physicians and are routinely
used by pharmaceutical companies to monitor disease incidence
and anticipate drug or vaccine sales. So far however, this resource
has remained largely untapped by epidemiologists and public
health researchers. A few promising studies have suggested that
electronic claims data may be useful to monitor disease patterns of
diarrheal and respiratory viruses in the US and evaluate pediatric
vaccine coverage in Germany [11,12,13,14]. Here we demonstrate
the use of electronic medical claims records to monitor local and
regional respiratory virus activity during pandemic and inter-
pandemic seasons in the US.
Data and Methods
Ethics
All patient records and information were anonymized and de-
identified prior to being handed over to researchers; all records
were part of routinely collected information for health insurance
purposes. Dr Farid Khan, Director of Advanced Analytics, IMS
Health, granted access to the patient data. The database is not
accessible online but researchers interested in gaining access to the
data should refer to the IMS Health website: http://www.
imshealth.com/portal/site/imshealth. In keeping with similar
epidemiological analyses of large-scale insurance administrative
databases, no institutional board review was sought. Further, all
statistical analyses were based on aggregated incidence time series
rather than individual patient-level information.
General approach
Our general approach is to compare weekly influenza indicators
derived from electronic medical claims data against reference
influenza surveillance time series, and against control time series
unrelated to influenza (such as RSV surveillance data). Our
statistical measures include correlations in weekly incidences, peak
timing and seasonal estimates of epidemic intensity. Additionally
we use permutation tests to show that the estimated correlations
are stronger than those expected by chance between incidence
time series that share common winter seasonality, so as to confirm
that medical claims data capture signals truly specific of influenza
activity. Analyses are conducted at the national, regional, and local
scales, and stratified by age group.
Data Sources
IMS Health Medical Claims Data. We used data main-
tained by IMS Health, a private data and analytics business that
collects de-identified electronic CMS-1500 medical claim forms
from full-time office-based active physicians throughout the US.
Claims data are sourced from the practice management software
vendors directly from the physician’s office, or from the
intermediary billing systems that coordinate the insurance claim
transactions. In 2009, there were 560,433 active physician
practices in the US of which IMS Health collected data from
354,402, or an approximate coverage rate of 61.5%. IMS Health
receives the records within 1–2 weeks of the patient’s visit. For
validation purposes, we focused here on historic IMS Health data
from July 2003 to June 2010. Claims data were kindly compiled by
IMS Health for research purposes under a collaborative agree-
ment with the authors.
Diagnoses are coded in the physician offices using international
classification of diseases, 9th revisions (ICD-9). We extracted visits
for different outcomes, including ILI and RSV, as well as the total
number of visits for any reason for denomination purposes. We
created weekly time series based on the date of office visit. Several
ILI case definitions were tested with the expectation that the most
appropriate definition would produce a large and geographically
heterogeneous spike in disease rates during the 2009 A/H1N1
influenza pandemic period, as observed in other surveillance
datasets [15], and capture the timing and intensity of influenza
epidemics in the pre-pandemic period. Further, a suitable ILI
definition had to generate sufficient disease volume to ensure
stable weekly time series at the city level.
Based on preliminary analyses and previous work exploring the
spatial dynamics of the 2009 influenza pandemic [11], we elected
to use an ILI definition that includes a direct mention of influenza,
or fever combined with a respiratory symptom, or febrile viral
illness (ICD-9 487-488 OR [780.6 and (462 or 786.2)] OR
079.99). Code 079.99 was identified as the most commonly used
diagnosis code for patients for whom the physician prescribed
oseltamivir during the pandemic period. Few patients received an
influenza specific code 487–488, a finding that may reflect that few
physician offices utilized rapid influenza tests during the pandem-
ic, following CDC guidelines to focus laboratory resources on the
most severe cases [16]. To investigate the specificity of IMS-ILI
data for influenza and test the suitability of IMS data for
monitoring other winter-seasonal viruses, we also created RSV
diagnoses time series (IMS-RSV), based on three RSV-specific
ICD-9 codes: 079.6 (RSV infection), 466.11 (RSV-bonchiolitis)
and 480.1 (RSV pneumonia).
Weekly incidence time series were compiled and broken down
by 10 administrative regions (Text S1) and 4 age groups (under
5 yrs, 5–29, 30–59, 60 and over). Regional population size
estimates were available from the US census [17]. To test the
performances of the IMS-ILI data locally, we also compiled
weekly incidence time series for 21 cities within New York State
based on the first 3-digits of the physician’s zip code.
All patient records and information were anonymized and de-
identified; all records were part of routinely collected information
for health insurance purposes. In keeping with similar epidemi-
ological analyses of large-scale insurance administrative databases
[11,12,13,14], no institutional board review was sought. Further,
all statistical analyses were based on aggregated incidence time
series rather than individual patient-level information.
Reference influenza surveillance data. Publicly-available
influenza surveillance data from 2003–2010 were obtained from
two separate reference systems maintained by the CDC: (1) The
Outpatient Influenza-like Illness (ILI) Surveillance Network and
(2) the US Influenza Virologic Surveillance System [2] (see also
[18]). The CDC-ILI Surveillance system consists of a network of
healthcare providers who record the weekly proportion of patients
presenting with non-specific signs and symptoms that meet a case
definition of influenza like illness [1]. CDC Virus Surveillance data
come from ,140 laboratories throughout the US that report the
total number of respiratory specimens tested and the number of
laboratory tests positive for influenza virus on a weekly timescale
[1]. Both of these databases are available at the national and
regional levels (Text S1).
Negative control reference surveillance data (RSV). We
also compiled weekly national data on laboratory-confirmed RSV
activity during 2003–2010 from the CDC’s National Respiratory
Medical Claims Data for Influenza Surveillance in the US
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and Enteric Virus Surveillance System [9]. These data were used
both to validate the IMS-RSV indicator and as a non-influenza
control for IMS-ILI indicators. If IMS-ILI data are specific of
influenza activity, we would expect IMS-ILI time series to be
strongly correlated with reference influenza surveillance time
series, and far less so with reference RSV surveillance time series.
Local influenza surveillance data. To evaluate the perfor-
mances of IMS-Health at a local level, we focused on New York
City, where disease surveillance is particularly well-established
[3,19,20]. We used weekly city-level syndromic ILI surveillance
during 2003–2010, based on 95% of emergency department visits,
which are reference influenza time series included in the CDC-ILI
dataset for the broader mid-Atlantic region [3,19,20].
We also document 2009 pandemic disease patterns in 21 cities
or county regions of New York State based on medical claims
data, as there was important spatial heterogeneity in pandemic
activity in this state [3,11].
Statistical approach
Study period and spatial scales. We compared weekly ILI
and RSV indicators based on medical claims with weekly
reference surveillance data from July 2003 to June 2010. This
period included 6 pre-pandemic seasons (July 2003–June 2004,
July 2004–June 2005, July 2005–June 2006, July 2006–June 2007,
July 2007–June 2008, July 2008–April 2009), and the spring and
fall 2009 A/H1N1 pandemic waves (May–Aug 2009 and
September 2009–June 2010).
The spatial scale of most of our analyses was the region or city,
except for comparisons with RSV laboratory-confirmed surveil-
lance, for which retrospective data were available only nationally.
Influenza incidence measures. For week t and region i, we
defined the IMS-ILI incidence indicator as the ratio of all ILI visits
in the IMS dataset to the total number of IMS visits that week, per
100,000 population, as in [11]:
IMS_ILI_incidence(t,i) = [(IMS_ILIt,i/IMS_visitst,i)]*
[(populationi/100,000)].
This indicator is an extension of the ILI incidence ratio used by
CDC and New York City [18], with additional standardization for
population size. The IMS-RSV incidence indicator was created in
the same way as the IMS-ILI indicator. To aggregate IMS data
nationally, we weighted weekly regional incidence estimates by the
number of physicians participating in surveillance in each week
and region.
We defined laboratory-confirmed influenza virus activity in
region i and week t as the standardized number of influenza
specimens testing positive for influenza, following:
Virus_activity(t,i) = flu_positivest,i,/total_specimens_testeds,i
Where flu_positivest,i, is the number of samples testing positive for
influenza in week t and region i, total_specimens_testeds,i is the
total number of samples tested in influenza season s and region i
[7]. An alternative is to standardize by the weekly number of
specimens tested (weekly percent virus positive), but this indicator
is more sensitive to sampling issues at the regional level, especially
at the start and end of the influenza season. We used the same
standardization for RSV laboratory-surveillance data.
Weekly correlation between surveillance time series. To
investigate whether the IMS-ILI indicator provided accurate
measurement of influenza epidemic patterns and following earlier
work [3,18], we computed the week-by-week Pearson’s correlation
between IMS-ILI and reference influenza surveillance time series
Since the estimated correlation could be explained in part by
shared winter seasonality across disease datasets, we also computed
the expected level of correlation under the null hypothesis where
correlation originates exclusively from winter seasonality rather
than influenza-specific factors. To do so, we generated 1,000
simulated datasets for each region and surveillance system by
permuting seasons.
A complementary test of the specificity of medical claims for
influenza surveillance was obtained by computing the correlation
between the IMS-ILI indicators and reference RSV surveillance
time series. These indicators share common winter seasonality but
are presumably prone to independent yearly and weekly
fluctuations specific to influenza and RSV.
Influenza and RSV peak timing. We compared the peak
timing of disease activity each season (defined as the week of
maximum weekly IMS- ILI incidence, IMS-RSV incidence,
CDC-ILI incidence, CDC influenza virus activity, and CDC
RSV activity in any given season). We computed the difference in
peak timing per season, and report the average and range of
differences by region.
Seasonal intensity of influenza and RSV epidemics. To
obtain a summary measure of influenza intensity by season, we
applied Serfling seasonal regression model to both medical claims
and reference ILI time series [3,21,22,23]. The Serfling approach
assumes that background non-influenza ILI incidence follows a
seasonal pattern, and that background seasonality does not
fluctuate between years. In this approach, a linear regression
model including harmonic terms and time trends is fitted to non-
influenza weeks (May-Oct), after exclusion of both pandemic
seasons. The model provides a seasonal baseline of the expected
level of ILI activity when influenza does not circulate. In
consequence, the burden of influenza on ILI can be estimated as
the cumulative difference between observed and baseline ILI each
respiratory season, which is a proxy for seasonal influenza
intensity. We repeated the analysis for all age and age-specific
data. A similar approach was used to compute seasonal estimates
of RSV intensity from weekly IMS-RSV indicators.
From laboratory-confirmed influenza time series, we defined
influenza seasonal intensity as the total virus percent positive each
respiratory season ( = sum of all influenza positive specimens/sum
of all specimens tested during the season), as in CDC summary
reports [2]. A similar approach was used to compute RSV
intensity from weekly laboratory-confirmed RSV surveillance. No
age breakdown was available for CDC’s viral activity data.
All analyses where performed in R; scripts are available from
the authors upon request.
Results
Regional comparisons
Overall patterns in influenza incidence. Weekly regional
influenza time series are displayed in Figure 1 for three
surveillance systems for the period 2003–2010: IMS-ILI, CDC-
ILI and CDC laboratory-confirmed influenza viral activity. All
datasets were characterized by strong winter seasonal peaks during
November-March, except for the unusual occurrence of spring
and fall pandemic peaks in 2009 in all regions. Between-season
fluctuations in influenza intensity were also observed, as expected
from variation in circulating strains and levels of population
immunity. All three surveillance systems captured the moderately-
sized spring 2009 pandemic wave in New England, and a large
spring wave in the New York City metropolitan region. In other
regions, laboratory-confirmed virus activity tended to overestimate
the impact of the pandemic spring wave, relative to the other
systems (Figure 1).
Week-to-week influenza incidence correlation. All three
influenza surveillance datasets were strongly synchronous, as
evidenced by high average week-to-week correlation across the 10
Medical Claims Data for Influenza Surveillance in the US
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regions (Table 1, all P,0.001). The IMS-ILI dataset was
particularly highly correlated with the two CDC surveillance
systems, with an average correlation above 0.89 (range across
regions and indicators, 0.80–0.97, P,0.001). The lag maximizing
the correlation between IMS-ILI and CDC-ILI time series ranged
between 0 and 1 wk across regions, indicating a slight lead in IMS
Health data. Similarly, IMS-ILI led CDC viral activity indicators
by 0–1 wk.
A season-by-season analysis revealed a clear drop in correlation
during the 2009 spring pandemic period, relative to pre-pandemic
seasons (average correlation in spring 2009, 0.32–0.45, range
across regions (20.50; 0.89); Text S1). All correlations returned to
high levels during the fall 2009 pandemic period (rho.0.88).
Permutations of respiratory seasons resulted in much lower
week-to-week correlation between the regional incidence time
series than in the original analysis (correlation ranging between
20.08; 0.67 across shuffled datasets; P,0.001 for difference with
original data). These results indicate that winter seasonality alone
was insufficient to explain the high level of synchrony observed
between these influenza surveillance time series.
Figure 1. Weekly time series of IMS Heath medical claims influenza-like-illness (ILI, red line), and reference influenza surveillance
time series, including CDC-ILI (dashed black line), and CDC laboratory influenza virus surveillance (dashed blue line), by region,
from July 7, 2003 through May 23, 2010. All time series have been rescaled for graphing purposes.
doi:10.1371/journal.pone.0102429.g001
Medical Claims Data for Influenza Surveillance in the US

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Medical Claims Data for Influenza Surveillance in the US
PLOS ONE | www.plosone.org 5 July 2014 | Volume 9 | Issue 7 | e102429
Comparison of influenza peak timing. Peak timing
provides a complementary measure of synchrony between
influenza surveillance systems. All three systems exhibited high
agreement in estimated influenza peak week across all regions
(average correlation $0.91, Table 1). Synchrony was particularly
high between IMS-ILI and CDC laboratory-confirmed virus
activity (average rho = 0.97), including during the pandemic
period (Table 1, Figure 2). Results were robust to national
aggregation of the data (Figure S1).
Comparison of seasonal influenza intensity. Although
the above comparisons of week-to-week fluctuations and peak
timing suggest a high level of synchrony between surveillance
datasets, especially in inter-pandemic seasons, there was less
agreement in seasonal estimates of ‘‘excess’’ influenza intensity
derived from Serfling models (Table 1, Figure 3). Correlation
between seasonal excess ILI estimates in IMS and CDC
surveillance was moderate (average rho = 0.52, range across
regions 0.09–0.92), with non-significant correlations in 7 of 10
regions (P$0.29). Correlation in seasonal intensity was even
weaker between IMS surveillance and CDC virus activity (average
rho = 0.11), with no region exhibiting significant correlation.
Similarly, correlation in seasonal influenza intensity estimates
was low between the two surveillance systems maintained by CDC
(average rho = 0.49 between CDC-ILI and CDC virus activity),
with only 2 regions showing significant correlation (Table 1).
Age patterns. Next, we repeated the previous analyses
stratified by four age groups (Table 2; see also Figure S2 for
age-specific time series). Correlations in weekly incidences and
peak timing remained excellent between IMS-ILI and CDC-ILI
for intermediate age groups (school-age children and young adults,
average rho$0.84), and more moderate among younger children
and seniors. In contrast, agreement in seasonal intensity estimates
between surveillance systems was strongest among seniors. Age-
specific CDC-ILI time series tended to be noisier for seniors, as
compared with other age groups, with most intense fluctuations in
the first 3 years of the study period. IMS-ILI time series in children
under 5 years displayed semi-annual peaks in summer and winter
in North-Eastern US, which remained unexplained and did not
coincide with influenza or RSV activity (Figure S3). Nevertheless,
pediatric IMS surveillance time series accurately captured non-
overlapping influenza and RSV activity in South-Eastern US
(Figure S4).
Analysis of RSV patterns
To check the specificity of medical claims data to monitor
influenza activity, we compared IMS-ILI indicators against
national reference surveillance data for RSV. The IMS-ILI
indicator was significantly less correlated with reference RSV
data than with reference influenza indicators on a national scale
(week-to-week correlation, rho$0.93 with CDC-ILI and influenza
viral activity, v. rho = 0.33 with laboratory-confirmed RSV, P,
0.05, Table 3). This analysis also confirmed the slight lead of the
IMS data over traditional surveillance when datasets are
aggregated nationally. Similarly, peak timing was more synchro-
nous between IMS-ILI and reference influenza surveillance than
with reference RSV data. Seasonal estimates of epidemic intensity
were significantly correlated between the IMS-ILI and CDC-ILI
surveillance systems, but not in the other datasets (Table 3).
We also check the consistency of RSV indicators derived from
medical claims data with reference RSV time series. The IMS-
RSV indicator was highly synchronized with reference RSV
laboratory surveillance data, with a 0-week lag maximizing
Figure 2. Synchrony in peak timing between the 3 surveillance systems, IMS-ILI, CDC-ILI, and CDC laboratory-confirmed virus
activity, by region. Red symbols illustrate the comparison between IMS-ILI (y-axis) and CDC laboratory surveillance (x-axis); while green symbols
represent the comparison between IMS-ILI (y-axis) and CDC-ILI (x-axis). Dots represents 6 pre-pandemic seasons, 2003–04 to 2008–09; squares
represent the spring 2009 pandemic wave, and triangles the main pandemic wave in fall 2009.
doi:10.1371/journal.pone.0102429.g002
Medical Claims Data for Influenza Surveillance in the US
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correlation between these datasets (rho$0.94, P,0.0001, for
week-to-week incidence and peak week correlation, Table 3).
Seasonal estimates of RSV intensity were moderately correlated
between the two datasets (rho = 0.77, P = 0.03, Table 3).
City-level influenza disease patterns
Next, we explored city-level disease curves (Figure 4). We focus
on the 2009 pandemic period in 21 cities and counties in New
York State, for which spatial heterogeneity has been well
documented [3,11]. Influenza pandemic patterns appear highly
heterogeneous at such a local scale. In particular, the New York
City boroughs display intense influenza activity in spring 2009
followed by a moderate outbreak in fall 2009, while locations in
upstate New York experienced a dominant fall wave. Comparison
of IMS-ILI time series for 4 boroughs of New York City with
available data (Manhattan, Queens, Bronx and Brooklyn),
revealed high consistency in IMS surveillance within this local
area (Figure 4: pairwise weekly correlation $0.87; P,0.0001).
This analysis confirms the robustness of the IMS system for local
disease monitoring, as we would expect high population connec-
tivity within New York City, resulting in highly synchronous
disease patterns between boroughs.
Additional comparison of IMS-ILI indicators for New York
City against locally available reference influenza surveillance data
reveals strong synchrony between datasets (Figure 5). There was
high correlation in weekly incidences (rho = 0.86, P,0.0001), and
excellent correlation in peak timing (rho = 0.99, P,0.0001), and
seasonal intensity (rho = 0.93, P,0.001). Reassuringly, the spring
wave of the 2009 pandemic appeared as an outlier in both
datasets, confirming the unusually pronounced first wave of A/
H1N1 pandemic virus activity in this city.
Discussion
Although there has been important progress in influenza
surveillance systems in recent years [1,3,19,20], highly-resolved
spatial disease data based on medical diagnoses are still lacking [3].
Figure 3. Comparison of influenza seasonal intensity measured by the 3 surveillance systems, IMS-ILI, CDC-ILI, and CDC laboratory-
confirmed virus activity, by region. Red symbols illustrate the comparison between IMS-ILI (y-axis) and CDC laboratory surveillance (x-axis); while
green symbols represent the comparison between IMS-ILI (y-axis) and CDC-ILI (x-axis). Dots represents 6 pre-pandemic seasons, 2003–04 to 2008–09;
squares represent the spring 2009 pandemic wave, and triangles the main pandemic wave in fall 2009. As regards ILI, intensity is based on excess
incidence over baseline each season, estimated from Serfling seasonal regression. As regards CDC virus surveillance, intensity is based on the
cumulative percent positive each season (sum of virus positives/sum of specimens tested).
doi:10.1371/journal.pone.0102429.g003
Table 2. Age-specific correlations between IMS-ILI and CDC-ILI on a regional scale, 2003–04 to 2009–10.
Outcome/Age group ,5 yrs 5–19 yrs 20–64 yrs Over 65 yrs
Weekly incidence 0.72 (0.64–0.81) 0.89 (0.81–0.95) 0.84 (0.72–0.93) 0.70 (0.41–0.86)
Peak week 0.76 (0.41–0.96) 0.98 (0.92–1) 0.87 (0.5–0.99) 0.68 (0.21–0.96)
Intensity 0.54 (0.27–0.80) 0.28 (20.33–0.93) 0.64 (0.43–0.9) 0.76 (0.53–0.97)
Values indicate average Pearson correlation coefficients across 10 regions (range is provided in parentheses); values in bold are significant (P,0.05).
doi:10.1371/journal.pone.0102429.t002
Medical Claims Data for Influenza Surveillance in the US
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We have shown here that medical claims-based ILI indicators
derived from IMS Health accurately capture weekly fluctuations
and timing of influenza activity in all 10 US regions. Our analyses
indicate that high-volume all-age ILI indicators are reliable during
inter-pandemic and pandemic seasons and can be broken down by
age groups and fine geographical areas. Further, comparisons
against control RSV surveillance time series confirm the specificity
of the IMS-ILI indicator for influenza. In contrast, we found weak
agreement between the various surveillance systems in their
seasonal estimates of influenza intensity, especially for school-age
children.
Table 3. Correlations between IMS indicators for ILI and RSV activity vs traditional influenza surveillance datasets maintained by
the CDC.
IMS-ILI indicator and: IMS RSV indicator and CDC RSV activity
Outcome CDC-ILI CDC influenza viral activity CDC RSV activity
Weekly incidence 0.97 (1) 0.93 (0) 0.33 (0)* 0.94 (0)
Peak week 0.99 0.97 0.21 0.97
Intensity 0.90 20.10 0.43 0.77
Correlation between IMS-ILI and CDC RSV laboratory-confirmed viral activity can be considered as a control comparison testing the specificity of IMS-ILI for influenza
surveillance. Analyses performed at the national scale, 2003–04 to 2009–10. Values indicate Pearson correlation coefficients; values in bold are significant (P,0.05).
*Correlation for this control comparison is significantly weaker than for the other comparisons (P#0.05), indicating that the IMS-ILI indicator is specific of weekly
influenza activity while the IMS RSV indicator is specific of weekly RSV activity.
doi:10.1371/journal.pone.0102429.t003
Figure 4. Spatial variation in local influenza activity: 2009 influenza pandemic patterns in 21 cities and county regions of New York
State. Weekly IMS-ILI indicators are represented for the period May 2009 to April 2010.
doi:10.1371/journal.pone.0102429.g004
Medical Claims Data for Influenza Surveillance in the US
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The level of correlation found between reference CDC-ILI
surveillance data and IMS-ILI indicators (range across regions
0.83–0.97) compares favorably to that reported for Google Flu
Trends (range across regions 0.84–0.96, [18]). Google Flu Trends
were deliberately calibrated against CDC-ILI surveillance, relying
on a set of Google search queries that optimized the correlation
between the two systems [24]. However, Google Flu Trends were
unable to capture the spring wave of the 2009 pandemic,
prompting a major revision of the algorithm [3,25]. In contrast,
IMS-ILI surveillance was not calibrated against CDC surveillance
Figure 5. Comparison of the IMS-ILI indicator for New York City (top panel) against reference surveillance data available locally
from emergency department (ED) visits (middle panel). Seasonal regression models are fitted to both time series, as explained in the text
(blue dots represent non-epidemic observations used to fit the model). The bottom panels display correlations in weekly incidences, peak weeks and
seasonal intensity estimates (red dots; seasonal influenza; blue dots; fall 2009 pandemic wave; green dot; spring 2009 pandemic wave) between the
IMS dataset and reference data.
doi:10.1371/journal.pone.0102429.g005
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but nevertheless accurately captured increased influenza activity in
the Boston and New York regions in May-June 2009, two regions
particularly affected by the spring pandemic wave [3,15]. Other
limitations of the updated Google Flu Trends algorithm include
the failure to capture the correct timing and intensity of the recent
and well-publicized 2012–13 influenza season at various geo-
graphic scales, perhaps due to changes in media attention [3,4].
Importantly, the gold standard for influenza surveillance remains
laboratory-confirmed viral activity. It is noteworthy that influenza
viral activity was more highly correlated with IMS-ILI surveillance
than with Google Flu Trends (rho = 0.89 v. 0.70 for regional data,
this study and [18]). These encouraging results suggest that IMS-
ILI may be a more specific indicator of influenza patterns than
Google Flu Trends.
Using retrospective IMS Health data based on the actual day of
the physician’s visit, we identified a lead of about 0–1 week
between IMS-ILI and reference CDC influenza indicators,
indicating increased timeliness of IMS data. The slight lag
associated with reference surveillance systems, relative to IMS
Health data, may result from delays associated with laboratory
testing and temporal aggregation of disease encounters. In
contrast, past work suggests there is essentially no lag between
reference influenza surveillance systems and Google Flu Trends in
the US [18]. Here we focused on providing a historical validation
of the IMS Health data, and did not attempt to test the real-time
availability of these data. However, if IMS Health claims data
were to be used for prospective surveillance purposes, timeliness
would depend on the ability to generate timely weekly reports,
perhaps based on a known pattern of trickling in of medical claims
following physician encounters. Our strategy of stabilizing the
IMS-ILI indicator by denominating with the total number of visits
will likely secure the reliability of IMS Health data in near real-
time use, even before all claims have been submitted.
The level of agreement in estimates of seasonal intensity by the
various influenza surveillance systems was only moderate or weak,
especially for school-age children. This is not surprising perhaps as
the intensity of an epidemic is more difficult to capture than its
timing [26]. As with any ILI surveillance system, IMS-ILI and
CDC-ILI data include a background level of activity originating
from the contribution of non-influenza respiratory pathogens,
which can be filtered by seasonal regression models [22]. This
approach however was insufficient to provide a high level of
correlation in seasonal intensity estimates at the regional scale in
our study. It is possible that different proportions of pediatricians
in the IMS and CDC surveillance systems, sample sizes issues,
and/or the increased contribution of non-influenza pathogens at
younger ages, obscures comparisons of intensity. Interestingly,
IMS-ILI data in young children were markedly different from
reference RSV time series, suggesting these indicators do not
capture RSV activity patterns in a major way.
Although laboratory-confirmed virus activity is highly specific
for influenza, it remains unclear whether such data should be
considered a gold standard for epidemic intensity. Between- season
variation in sampling intensity and diagnostic sensitivity may bias
the percent virus positive metric, as can fluctuations in co-
circulating respiratory pathogens. For instance, the CDC-ILI and
IMS-ILI indicators had similar intensity in spring 2009, while at
the same time departing from influenza virus surveillance data,
suggesting an inflated impact of the spring 2009 pandemic wave in
laboratory surveillance. Intensified sampling of respiratory spec-
imens during the first few weeks of pandemic activity, combined
with a minimal contribution of co-circulating respiratory patho-
gens in the spring, would explain these discrepancies. On the other
hand, the percent virus positive metric never exceeds ,40% even
in the most severe influenza seasons, perhaps due to detection
issues [27]. Consequently, others have proposed a combination of
ILI and percent virus positive as the most appropriate indicator of
influenza intensity [27]. Although attractive and particularly well
correlated with influenza-related mortality [28], this composite
indicator is not available at a local scale where viral sampling
remains too sparse. Similarly, the integration of local Google Flu
Trends indicators with regionally-available percent virus positive
data has been put forward to monitor influenza activity in US
cities [29]. The performances of this hybrid surveillance approach
should be quantified however, especially as Google Flu Trends is
prone to important under- and over-estimation issues [3]. Overall,
further theoretical and simulation work should concentrate on
identifying the most appropriate indicators of disease intensity at
weekly and seasonal time scales and evaluate putative biases.
Although we were unable to systematically validate city-level
IMS-ILI indicators throughout the US due to unavailability of a
gold standard at the relevant spatial scale, our comparison focused
on New York City was promising. At the local level, IMS-ILI data
revealed important spatial heterogeneity in pandemic patterns
between cities in New York State, together with great consistency
between well-connected boroughs of New York City, indicating
the robustness of this system to monitor local disease spread.
Although a thorough validation of IMS-RSV disease indicators
at local and regional scales was beyond the scope of this study, we
noted a clear promise in the IMS data for tracking RSV activity.
More work in this area would be worthwhile as local indicators of
RSV activity are urgently needed to guide the timing of
prophylaxis in individual locations [9,10], until vaccines become
available. Further, availability of local RSV data could help shed
light on the transmission dynamics of this less-studied pathogen
and the surprising level of spatial heterogeneity in seasonal
epidemics [10,30].
Our study is subject to several limitations. Our study period was
relatively short, 2003–2010, which includes only 6 inter-pandemic
and 2 pandemic seasons. Although IMS surveillance started in
2001, the number of participating physicians and data volume
increased substantially in the first two years, which we chose to
discard from this study. Nevertheless, we were able to capture a
variety of influenza seasons dominated by all 3 influenza subtypes,
ranging from mild and double-peaked winter epidemics (2006–07),
to the localized spring 2009 pandemic wave, and the very spiky
and unusual fall 2009 pandemic wave. Further, we did not test the
performances of IMS Health data for real time surveillance in a
prospective manner, which would require a careful study of the
dynamics of accumulation of claims into the IMS Health data
warehouse.
In summary, we have shown that the medical claims-based
surveillance is a very promising tool to study influenza and RSV
activity at regional and local scales in inter-pandemic and
pandemic seasons. While there has been great progress in the
last decade in building sophisticated spatial simulation models of
pandemic influenza spread in the US and globally [31,32,33],
proper model validation against empirical disease patterns is still
sparse due to the lack of fine-grained epidemiological data [11].
There has been considerable interest in novel surveillance systems
such as Google Flu Trends to fill the void, particularly in large
cities such as New York [34]. It has recently become clear however
that search query indicators may not always capture true disease
patterns and miss critical epidemiological features such as out-of-
season pandemic outbreaks [3]. Alternative choices include high-
volume medical databases maintained in the private sector, such as
IMS Health, and similar data streams generated in the public
sector, such as Biosense [35,36] and Electronic Health Records
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from ambulatory clinics [37]. One important obstacle to a wider
use of large medical claims databases is perhaps their prohibitive
cost for public health research, although this will become less of an
issue in the future as the cost of electronic health data is declining.
In conclusion, we believe medical claims data offer a unique
opportunity to provide rapid disease information to the scientific
and public health communities for local situational awareness, to
refine existing influenza transmission models, and support
pandemic response in future outbreaks.
Supporting Information
Figure S1 Synchrony in peak timing between IMS-ILI
indicators and reference surveillance systems, including
CDC-ILI (A), CDC laboratory-confirmed influenza virus
activity (B), and CDC laboratory-confirmed RSV activity
(C). Comparisons are based on nationally-aggregated data. Red
circles represent 6 pre-pandemic seasons, 2003–04 to 2008–09;
green dots represent the spring 2009 pandemic wave and blue dots
the main pandemic wave in fall 2009.
(TIF)
Figure S2 Age-specific ILI time series in the Boston
region (region 1) based on CDC surveillance and IMS
Health.
(TIF)
Figure S3 Comparison of IMS-ILI, CDC-ILI and IMS-
RSV indicators in the Boston region (region 1) for
children under 5 yrs. Note the semi-annual pattern of activity
in IMS-ILI data (large peak in winters and smaller peaks in
summers), which is most pronounced in the North-East. The
bottom panel suggests that IMS-ILI does not align with RSV
activity but instead accurately captures unusually early influenza
activity in fall 2003 (severe A/H3N2 Fujian season) and fall 2009
(A/H1N1 pandemic; see also Figure S4).
(TIF)
Figure S4 Comparison of IMS-ILI, CDC-ILI and IMS-
RSV indicators in the Atlanta region (region 4), for
children under 5 yrs. In this region, RSV is known to display
very early timing of activity and predates influenza in most years,
except for the 2003–04 influenza season and 2009 fall pandemic
wave. The bottom panel confirms that the pediatric IMS-ILI
indicator does not capture RSV activity patterns (see also Figure
S3).
(TIF)
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